Literature DB >> 12401194

Biological effects of group IIA secreted phosholipase A(2).

Lucía Fuentes1, Marita Hernández, María Luisa Nieto, Mariano Sánchez Crespo.   

Abstract

Group IIA secreted phospholipase A(2) (sPLA(2)-IIA) is the most abundant element in human tissues of a large family of low molecular weight phospholipases A(2), which shows properties different from those displayed by the cytosolic phospholipase A(2) involved in the release of arachidonic acid. sPLA(2)-IIA behaves as a ligand for a group of receptors inside the C-type multilectin mannose receptor family and also interacts with heparan sulfate proteoglycans such as glypican, the dermatan/chondroitin sulfate-rich decorin, and the chondroitin sulfate-rich versican, thus being able to internalize to specific compartments within the cell and producing biological responses. This review provides a short summary of the biological actions of sPLA(2)-IIA on intracellular signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401194     DOI: 10.1016/s0014-5793(02)03401-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  Biological and structural characterization of a new PLA2 from the Crotalus durissus collilineatus venom.

Authors:  M H Toyama; D O Toyama; Paulo P Joazeiro; E M Carneiro; L O S Beriam; L S Marangoni; A C Boschero
Journal:  Protein J       Date:  2005-02       Impact factor: 2.371

2.  Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner.

Authors:  Jun Saegusa; Nobuaki Akakura; Chun-Yi Wu; Case Hoogland; Zi Ma; Kit S Lam; Fu-Tong Liu; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

3.  Molecular basis of phospholipase A2 activity toward phospholipids with sn-1 substitutions.

Authors:  Lars Linderoth; Thomas L Andresen; Kent Jørgensen; Robert Madsen; Günther H Peters
Journal:  Biophys J       Date:  2007-09-07       Impact factor: 4.033

4.  Synthesis of oligo(ethylene glycol) substituted phosphatidylcholines: secretory PLA2-targeted precursors of NSAID prodrugs.

Authors:  Renato Rosseto; Joseph Hajdu
Journal:  Chem Phys Lipids       Date:  2010-01       Impact factor: 3.329

5.  Analysis of several PLA2 mRNA in human meningiomas.

Authors:  Yves Denizot; Rafael De Armas; Karine Durand; Sandrine Robert; Jean-Jacques Moreau; François Caire; Nicolas Weinbreck; François Labrousse
Journal:  Mediators Inflamm       Date:  2010-03-21       Impact factor: 4.711

6.  Inhibition of Human Group IIA-Secreted Phospholipase A2 and THP-1 Monocyte Recruitment by Maslinic Acid.

Authors:  Wei Hsum Yap; Nafees Ahmed; Yang Mooi Lim
Journal:  Lipids       Date:  2016-08-19       Impact factor: 1.880

7.  Phospholipases A2 in normal human conjunctiva and from patients with primary open-angle glaucoma and exfoliation glaucoma.

Authors:  Minna Helin; Seppo Rönkkö; Tuomo Puustjärvi; Markku Teräsvirta; Hannu Uusitalo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-01-15       Impact factor: 3.117

Review 8.  Phospholipase A(2), reactive oxygen species, and lipid peroxidation in CNS pathologies.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  BMB Rep       Date:  2008-08-31       Impact factor: 4.778

9.  Reduction of lipoxidative load by secretory phospholipase A2 inhibition protects against neurovascular injury following experimental stroke in rat.

Authors:  Md Nasrul Hoda; Inderjit Singh; Avtar K Singh; Mushfiquddin Khan
Journal:  J Neuroinflammation       Date:  2009-08-13       Impact factor: 8.322

10.  Harpalycin 2 inhibits the enzymatic and platelet aggregation activities of PrTX-III, a D49 phospholipase A2 from Bothrops pirajai venom.

Authors:  Rafael M Ximenes; Renata S Alves; Ticiana P Pereira; Renata M Araújo; Edilberto R Silveira; Marcelo M Rabello; Marcelo Z Hernandes; Veronica C G Soares; Daniel Bristot; Camila L Pires; Daniela O Toyama; Henrique H Gaeta; Helena S A Monteiro; Marcos H Toyama
Journal:  BMC Complement Altern Med       Date:  2012-08-27       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.